Australien - engelska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - caspofungin acetate, quantity: 55.49 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sucrose; mannitol; glacial acetic acid; sodium hydroxide - caspocip is indicated for: ? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics ? treatment of: - invasive candidiasis, including candidaemia - oesophageal candidiasis - invasive aspergillosis in patients who are refractory to or intolerant of other therapies

Singapore - engelska - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - caspofungin acetate 55.52mg equivalent to caspofungin - injection, powder, lyophilized, for solution - caspofungin acetate 55.52mg equivalent to caspofungin 50.00 mg/vial

Singapore - engelska - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - caspofungin acetate 77.69mg equivalent to caspofungin - injection, powder, lyophilized, for solution - caspofungin acetate 77.69mg equivalent to caspofungin 70.00 mg/vial

Irland - engelska - HPRA (Health Products Regulatory Authority)

teva b.v. - caspofungin acetate - pdr/conc/soln for infus - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Irland - engelska - HPRA (Health Products Regulatory Authority)

teva b.v. - caspofungin acetate - pdr/conc/soln for infus - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Europeiska unionen - engelska - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients.treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and/or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - caspofungin acetate -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - caspofungin acetate -

Kanada - engelska - Health Canada

teva canada limited - caspofungin (caspofungin acetate) - powder for solution - 50mg - caspofungin (caspofungin acetate) 50mg - echinocandins

Kanada - engelska - Health Canada

teva canada limited - caspofungin (caspofungin acetate) - powder for solution - 70mg - caspofungin (caspofungin acetate) 70mg - echinocandins